Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.
about
Variable characteristics of bacteriocin-producing Streptococcus salivarius strains isolated from Malaysian subjectsImportance of microbial natural products and the need to revitalize their discovery.Production, purification, sequencing and activity spectra of mutacins D-123.1 and F-59.1.In vivo activity of nisin A and nisin V against Listeria monocytogenes in mice.Site-directed mutations in the lanthipeptide mutacin 1140.Surface glycosaminoglycans protect eukaryotic cells against membrane-driven peptide bacteriocins.Improved production of sublancin via introduction of three characteristic promoters into operon clusters responsible for this novel distinct glycopeptide biosynthesisAntimicrobial nisin acts against saliva derived multi-species biofilms without cytotoxicity to human oral cells.Biomedical applications of nisin.Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics.Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP.Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance.Probiotics and its functionally valuable products-a review.Detection of putative new mutacins by bioinformatic analysis using available web tools.Multipronged approach for engineering novel peptide analogues of existing lantibiotics.The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.Manipulation of innate immunity by a bacterial secreted peptide: lantibiotic nisin Z is selectively immunomodulatory.In vitro studies indicate a high resistance potential for the lantibiotic nisin in Staphylococcus aureus and define a genetic basis for nisin resistanceCharacterization of the stereochemical configuration of lanthionines formed by the lanthipeptide synthetase GeoM.Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.
P2860
Q21558804-0B5E5F41-6811-4EC3-AB7D-39D91B489796Q31128037-721AD149-170F-41E1-B5A0-B35DE4C464D9Q33866461-3CC15E40-44C1-4538-A7FA-CA2FDCAB8249Q34572089-F61A5A89-54D6-4D26-BAC3-2AF67360B978Q34679435-01FFDE4F-CFB9-4340-845D-422E399EC28DQ34923184-7FB4D51E-8DED-46CF-93B2-71820D7BDAA0Q35108649-7161426F-A3A5-456A-9218-30DAB0D5B080Q35754137-7F2FEFD3-A142-45AB-8E56-9245257B5525Q36900890-B477645C-8A14-4AFF-93BC-F0D6AD6C5919Q37590315-7AB896DB-388B-45FE-A0A3-C3E0DFF37DBEQ37657138-7371316C-D0F7-4371-9BBE-8BD1BCD2BF7AQ38009935-1066FF72-D54E-4B7A-8339-C1640FC0A47DQ38102735-34140903-4F6F-4BB3-9251-08237A58B8FFQ38264640-1A1471EE-A022-4DDB-827C-37635BBE785EQ38500614-DD6E27FF-6FB6-4C6E-9660-D632D41FA775Q39097534-F56C799F-E597-4CAB-BEDC-87D1EA4C5FD4Q39251694-46C8BED0-D872-4B4B-91BB-EBD41098C4E3Q41885921-DB86E03B-B102-4703-AEBA-939BF0D12662Q42696478-AA61B883-3E9D-41A7-AB0D-E86BBBC74DCAQ52608578-8AC7D33C-72E2-44C7-BA1E-89D42379E19CQ55307893-13D5BB36-4566-43DF-8D39-CFC044C2C491
P2860
Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic potential of type ...... cationic peptide antibiotics.
@en
Therapeutic potential of type ...... cationic peptide antibiotics.
@nl
type
label
Therapeutic potential of type ...... cationic peptide antibiotics.
@en
Therapeutic potential of type ...... cationic peptide antibiotics.
@nl
prefLabel
Therapeutic potential of type ...... cationic peptide antibiotics.
@en
Therapeutic potential of type ...... cationic peptide antibiotics.
@nl
P2860
P1476
Therapeutic potential of type ...... cationic peptide antibiotics.
@en
P2093
Jd Hillman
Leif Smith
P2860
P304
P356
10.1016/J.MIB.2008.09.008
P577
2008-10-24T00:00:00Z